Using Protease Cascades to Detect Protein Targets
This federal contract opportunity has been awarded to on July 9, 2025.
Award Information
This solicitation resulted in an award to for approximately $109,998 on July 9, 2025. Similar contracts are typically issued by DEPT OF DEFENSE under 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
- Award Number
- HT9425-25-P-0098
- Award Amount
- $109,998
- Award Date
- July 9, 2025
Key Takeaways
- No response deadline specified - contact the agency for details
- Set-aside for No Set Aside businesses
- Work to be performed in FORT DETRICK, MD
- Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Contract Details
- Notice ID
- HT9425-25-P-0098
- Opportunity Type
- Award Notice
- Agency
- DEPT OF DEFENSE
- Sub-Agency
- DEFENSE HEALTH AGENCY (DHA)
- Office
- ARMY MED RES ACQ ACTIVITY
- Posted Date
- Wednesday, July 9, 2025
- Response Deadline
- Not specified
- PSC Code
- AJ11
- Set-Aside
- No Set Aside
- Place of Performance
- FORT DETRICK, MD, 21702
- Status
- Active
Description
Potomac Affinity Proteins, LLC received a sole source, firm-fixed price award for services necessary to develop a customized protease chain reaction (ProCR) assay for specifically detecting botulinum neuro toxins (BoNT) in support of the US Army Medical Research Institute of Infectious Diseases (USAMRIID). Potomac Affinity Proteins, LLC is the only source that demonstrates the unique capability to provide these research services. This requirement is highly specialized, complex, and unique to the proprietary technology developed by Potomac Affinity Proteins, LLC.
Why This Opportunity Matters
The Department of DEFENSE is seeking responses for research and development in biotechnology (except nanobiotechnology) with a set-aside for No Set Aside businesses in FORT DETRICK, MD. This set-aside designation means eligible businesses face reduced competition from larger firms.
Similar Opportunities
AJ11-VA Depleted Uranium Program PO 512C50314
Q-RNAscope In-House Assay
Low-cost, Connected, Digital Lateral Flow Platform to Detect Influenza A, Influenza B, and SARS-Cov -2 for use in Over-the-Counter (OTC) Settings
A-High Throughput Transcriptomics (HTTr)
human-derived monoclonal antibodies (mAbs) and viral recombinant antigens (Ags)
Browse Related
Looking for more opportunities?
Browse our full directory of government contracts
